Catalyst

Slingshot members are tracking this event:

Vanda Pharmaceuticals (VNDA) Expected to submit HETLIOZ filing to FDA in 2018 for Smith Magenis Syndrome (SMS) indication

Source Link:
https://seekingalpha.com/article/4053316-vanda-pharmaceuticals-vnda-presents-cowen-company-37th-annual-health-care-conference

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
VNDA Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Update on July 31 2019: Vanda expects to file a sNDA for HETLIOZ® for the treatment of Smith-Magenis Syndrome in the third quarter of 2019.  
https://vandapharmac...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Aug 19, 2019
Occurred Source:
https://www.fiercebiotech.com/biotech/fda-snubs-jet-lag-filing-for-vanda-s-sleep-disorder-med-hetlioz
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Smith-magenis Syndrome, Fda Review, Hetlioz
About Us
Media Center
Connect with Us
© 2026 Slingshot Insights. All rights reserved.